Related Experiment Video
Updated: Apr 14, 2026
09:15
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
4.2K
Progress in human tumour immunology and immunotherapy
1Division of Clinical Sciences, National Cancer Institute, Building 10, Room 2B42, 10 Center Drive, MSC 1502, Bethesda, Maryland 20892-1502, USA.
Nature
|May 18, 2001
Summary
Immunotherapies leveraging interleukin-2 can induce durable cancer regression. Identifying cancer antigens enables new treatments, boosting anti-tumour lymphocytes for effective cancer cell therapies.
Area of Science:
- Oncology
- Immunology
- Cancer Research
Background:
- Interleukin-2 (IL-2) administration in metastatic melanoma and kidney cancer patients demonstrates the potential of immunotherapy.
- Molecular identification of cancer antigens has paved the way for novel cancer immunotherapies.
- Existing research highlights the ability to generate anti-tumour lymphocytes through cancer antigen immunization.
Purpose of the Study:
- To explore the potential of immunological manipulations in achieving durable cancer regression.
- To investigate the development of effective immunotherapies based on molecularly identified cancer antigens.
- To understand the mechanisms by which cancer evades immune responses.
Main Methods:
- Administration of interleukin-2 to patients with metastatic cancers.
- Immunization of cancer patients with peptides derived from cancer antigens.
- Isolation and in vitro expansion of anti-tumour lymphocytes from immunized patients for cell-transfer therapies.
Main Results:
- Durable regression of metastatic cancer observed following interleukin-2 administration.
- Successful induction of high levels of lymphocytes with anti-tumour activity in immunized patients.
- Isolation of highly avid anti-tumour lymphocytes feasible for therapeutic applications.
Conclusions:
- Immunological approaches, including IL-2 therapy and antigen-specific immunization, show promise for durable cancer regression.
- Further research is needed to elucidate cancer's immune escape mechanisms for enhanced therapeutic strategies.
Related Concept Videos
02:17The Tumor Microenvironment
8.2K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
8.2K
01:27Tumor Immunotherapy
2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
01:30Cancer Vaccines
1.4K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.4K